Skip to content

Nuri B Farber

6 papers in the library · 115 citations · publishing 2003-2023

Papers

Sort Most recent Most cited

Change in patient‐centered outcomes of psychological well‐being, sleep, and suicidality following treatment with intravenous ketamine for late‐life treatment‐resistant depression

International Journal of Geriatric Psychiatry July 1, 2023 Benjamin Vanderschelden, M. A. Gebara, H. Oughli et al. 13 citations

To examine whether psychological well‐being, sleep, and suicidality improved with treatment with intravenous (IV) ketamine for late‐life treatment‐resistant depression (TRD).

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

The American journal of geriatric psychiatry December 1, 2022 H. Oughli, M. A. Gebara, A. Ciarleglio et al. 33 citations

Objective: Evidence-based treatment options for late-life treatment-resistant depression (TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of data on its safety and efficacy in older adults. Methods: In this pilot clinical trial, 25 adults aged ≥60 years with TRD received IV ketamine openly twice a week for 4 weeks; partial responders at the end of this...

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

Psychopharmacology January 22, 2021 J. Siegel, Ben J Palanca, Beau M Ances et al. 53 citations

Ketamine produces a rapid antidepressant response in over 50% of adults with treatment-resistant depression. A long infusion of ketamine may provide durable remission of depressive symptoms, but the safety, efficacy, and neurobiological correlates are unknown. In this open-label, proof-of-principle study, adults with treatment-resistant depression (N = 23) underwent a 96-h infusion of...

NMDA Antagonists for Treatment-Resistant Depression.

Handbook of experimental pharmacology 2019 Nuri B Farber

Fifteen to thirty percent of patients with major depressive disorder do not respond to antidepressants that target the monoaminergic systems. NMDA antagonists are currently being actively investigated as a treatment for these patients. Ketamine is the most widely studied of the compounds. A brief infusion of a low dose of this agent produces rapid improvement in depressive symptoms that lasts...

Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol

Frontiers in Psychiatry May 14, 2018 Ben J Palanca, Hannah R. Maybrier, Angela M. Mickle et al. 16 citations

Electroconvulsive therapy (ECT) employs the elective induction of generalizes seizures as a potent treatment for severe psychiatric illness. As such, ECT provides an opportunity to rigorously study the recovery of consciousness, reconstitution of cognition, and electroencephalographic (EEG) activity following seizures. Fifteen patients with major depressive disorder refractory to pharmacologic...

The NMDA receptor hypofunction model of psychosis.

Annals of the New York Academy of Sciences November 1, 2003 Nuri B Farber

Antagonists of the NMDA glutamate receptor, including phencyclidine (PCP), ketamine, and CGS-19755, produce cognitive and behavioral changes in humans. In rodents these agents produce a myriad of histopathological and neurochemical changes. Several lines of evidence suggest that a large number of these drug-induced effects are dose-dependent manifestations of the same general disinhibition...